BACKGROUND Treatment for claudication that is due to aortoiliac peripheral artery disease (PAD) often relies on stent
P eripheral artery disease (PAD) is 1 of the most prevalent cardiovascular diseases (1) , affecting up to 5% of individuals over 55 years of age (2) (3) (4) (5) (6) . Claudication is the most frequent symptom of PAD and is associated with significant disability and substantial reductions in patientreported health status and quality of life (7) .
Multiple clinical trials have demonstrated that supervised exercise (SE) is an effective treatment because it significantly improves walking performance (8) and quality of life (9, 10) . Despite this, access to SE is limited, because clinicians do not actively prescribe this claudication treatment, and it is usually not reimbursed by Medicare or by thirdparty payers.
Lower-extremity endovascular revascularization is 1 of the most frequent peripheral vascular procedures (11) . Over the last decade, the number of such procedures has increased 3-fold (12) . Although outcomes of aortoiliac artery stent placement for claudication in uncontrolled studies are excellent (13, 14) , it is also known that patients with PAD appreciate the benefits of low-risk interventions when available (15) . The
CLEVER (Claudication: Exercise Versus Endoluminal
Revascularization) study is a comparative effectiveness study that compared outcomes for aortoiliac stenting (ST) or SE with optimal medical therapy (OMT) at 6 and 18 months. The study, designed to measure a primary peak walking treadmill time outcome at 6 months, demonstrated that SE achieved a greater early functional status improvement compared with ST (16) . This paper describes the results of the CLEVER study at 18 months.
METHODS
STUDY DESIGN AND OVERSIGHT. The CLEVER study was a randomized, multicenter clinical trial conducted at 29 centers in the United States and Canada. The study was designed to test the hypothesis that ST plus optimal medical care (OMC) and SE plus OMT would be associated with a greater improvement in peak walking time (PWT) on a graded treadmill test than with OMT alone. The CLEVER study secondarily tested whether ST plus OMT resulted in more improvement in PWT than SE plus OMC. The study was approved by the U.S. Food and Drug Administration, the Canadian Therapeutic Products Directorate, and institutional review boards at all participating centers, and was supported by the National Institutes of Health National Heart, Lung, and Blood Institute. The study has been registered as NCT00132743 since August 19, 2005 , and was overseen by an independent data safety and monitoring committee. Details of the study design, methods, and early results were published previously (16, 17) . The lead author wrote the first draft of the manuscript, and all coauthors participated in and approved subsequent revisions. Moderate-to-severe claudication was defined as the ability to walk at least 2 min on a treadmill at 2 miles per hour at no grade, but <11 min on a graded treadmill test using the Gardner-Skinner protocol (18) . Walking 11 min on the Gardner-Skinner protocol is consistent with an approximately 5.5-MET workload, which is considered moderate-intensity physical activity (19) . All subjects were enrolled on the basis of the presence of at least a 50% diameter stenosis of the distal aorta or iliac arteries involving the more symptomatic leg, which was confirmed by either noninvasive vascular laboratory testing (n ¼ 92) or catheter angiography (n ¼ 19), as previously described (16) . Distal angiographic anatomy was not evaluated because individuals with claudication as a result of aortoiliac PAD are known to achieve substantial functional (treadmill) and quality-of-life benefit from aortoiliac ST, regardless of the presence of distal arterial stenosis (7) . Additionally, baseline angiographic study is invasive and was not considered necessary or appropriate for a study in which 2 of 3 treatment strategies were noninvasive.
RANDOMIZATION AND INTERVENTIONS. Randomization was designed to be unbalanced in order to achieve twice as many participants in the ST and SE Participants were randomized after consenting for study participation and undergoing eligibility testing. Potentially eligible study participants were screened at the discretion of the study site. The proportion that did not expire, withdraw consent, exit the study, or were not lost to follow-up before completion of the 18-month follow-up was 93 of 111 (84%). Of the 93 who remained in the study for the entire 18 months of follow-up, treadmill test data were available for 79 of 111 (71%) at 18 months. Of the 14 who remained in the study for the duration of followup but did not undergo the treadmill test at 18 months, there were 9 in ST, 2 in SE, and 3 in OMC. The reasons for 9 ST participants missing PWT were: 1) could not be contacted (1); 2) comorbid condition (recent laminectomy) (1); 3) out of 2-week window (2); and 4) refused (5, 3 of whom had crossed over to structured exercise). The reasons for 3 OMC participants missing PWT were: 1) comorbid condition (unknown) (1); and 2) no show (2). The reasons for 2 SE participants missing PWT were: 1) refused (1); and 2) unknown (1). Of the 14 patients who did not have the 18-month PWT, 7 had other 18-month endpoints collected, and 13 had QOL data collected by telephone. All study participants were confirmed to be alive at the 18-month follow-up interval, except for 1 person in SE who expired before the 6-month follow-up. 18M ¼ 18-month;
I/E ¼ inclusion/exclusion; OMC ¼ optimal medical care; PWT ¼ peak walking time; QOL ¼ quality of life; SE ¼ supervised exercise treatment;
ST ¼ stenting treatment. Statistical analyses were performed using SAS for Windows (version 9.1.3, SAS, Cary, North Carolina).
RESULTS
POPULATION. Study design and patient flow from enrollment through the 18-month endpoint assessment, Values are mean AE SD (n) or % (n/N). *Antiplatelet use means use either of aspirin, clopidogrel, or both.
BMI ¼ body mass index; COT ¼ claudication onset time on the graded treadmill test; DBP ¼ diastolic blood pressure; HbA1c ¼ glycosylated hemoglobin; HDL ¼ plasma high-density lipoproteins; LDL ¼ plasma low-density lipoproteins; PAD ¼ peripheral artery disease; PWT ¼ peak walking time on the graded treadmill test; SBP ¼ systolic blood pressure; TIA ¼ transient ischemic attack.
as well as reasons for missing follow-up, are shown in Figure 1 . Baseline characteristics of the 3 study groups were similar ( Table 1) . There were more participants with a history of stroke in the SE group compared with other groups, but subjects with residual neurological deficits that might affect walking performance were excluded from study participation. The baseline PWT demonstrated severe ambulatory limitation at slightly over 5 min, which was similar across treatment groups. The population that completed the 18-month follow-up was similar to the baseline population ( Table 1) ; there were no significant differences in baseline characteristics between the 79 patients who completed the 18-month treadmill test and the 32 patients who did not ( Table 1) . Table 1 ). Although participants who missed the 18-month treadmill test in all 3 treatment groups tended to have better outcomes at 6 months than those who complied, this analysis is flawed because more than one-half of those who missed the 18-month treadmill test also missed the 6-month treadmill test.
QUALITY OF LIFE. There were no baseline differences in quality of life among the treatment groups.
At 18 months, improvement in disease-specific scales (WIQ, PAQ) was statistically superior for ST and SE compared with OMC, but ST and SE differed significantly from each other (favoring ST) only for PAQ symptoms, PAQ treatment satisfaction, PAQ quality of life, and PAQ summary (Table 3, Figure 2 ).
SAFETY. There were 3 pre-specified major adverse events, all of which occurred in the first 6 months Values are mean AE SD (n) or difference (95% CI). The WIQ includes sections to ascertain PAD specificity and differential diagnosis, as well as 14 questions about walking distance, walking speed, and stair climbing. The PAQ consists of 14 questions designed to elicit information about disease-specific quality of life across a range of PAD-specific domains. *The p values are calculated using change scores, and are based on analysis of covariance adjusting for study center, baseline cilostazol use, and baseline value of the endpoint. †Baseline to 18-month change values were calculated only for participants for whom both baseline and 18-month data were collected.
PAQ ¼ Peripheral Artery Questionnaire; SF-12 ¼ Medical Outcomes Study Short Form-12; WIQ ¼ Walking Impairment Questionnaire; other abbreviations as in Tables 1 and 2. improved endothelial function, angiogenesis, and capillary density, oxidative metabolism and oxygen extraction, decreased blood viscosity, muscle innervation, and improved walking economy. The durability of the treatment effect of SE up to a year after termination of SE provides evidence that the benefits in treadmill walking are not solely due to a treadmill-specific training effect. This enrollment fraction is common and is similar to rates reported from most other randomized trials of similar populations (34, 35) . Another limitation is that of the 93 participants with 18 months of follow-up, treadmill test data at that interval were only available for 79 ( Figure 1) . Although the patients with and those without the treadmill test were similar ( Table 1) , it is impossible to be certain that the reasons for their missing data are random. 
